Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 168 clinical trials
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based

measurable disease
peritoneal cancer
endometrioid carcinoma
tumor debulking
fallopian tube
  • 392 views
  • 10 Feb, 2021
  • 42 locations
Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

who are PD-1/PD-L1 inhibitor nave and have progressed on a platinum based chemotherapy regimen.

pd-1 inhibitor
lung carcinoma
measurable disease
cancer chemotherapy
  • 0 views
  • 21 Feb, 2021
  • 44 locations
Platino-resistance in Ovarian Cancer

Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages). Patients will receive

ascites
ovarian cancer
  • 0 views
  • 25 Jan, 2021
  • 1 location
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

allocation to: Arm A: Sacituzumab govitecan (days 1, 8 q3w for eight cycles); Arm B: treatment of physicians choice (TPC, defined as capecitabine or platinum-based chemotherapy for

  • 0 views
  • 26 Jan, 2021
  • 32 locations
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer

treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Drugs used in

doxorubicin
pegylated liposomal doxorubicin hydrochloride
paclitaxel
ovarian cancer
thyroid dysfunction
  • 1729 views
  • 26 Feb, 2021
  • 212 locations
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy …

cancer
ROS1
solid tumor
  • 338 views
  • 05 Feb, 2021
  • 132 locations
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in patients with recurrent or metastatic head and neck cancer.

  • 0 views
  • 21 Feb, 2021
  • 138 locations
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.

  • 0 views
  • 13 Feb, 2021
  • 73 locations
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.

The OReO study will be a Phase IIIb, randomised, double-blind, placebo-controlled, multicentre study to assess the efficacy and tolerability of Olaparib retreatment, versus matching placebo, in non-mucinous epithelial ovarian cancer (EOC) patients (including patients with primary peritoneal and/or fallopian tube cancer).

olaparib tablets
ovarian cancer
bevacizumab
oxaliplatin
fallopian tube
  • 224 views
  • 30 Jan, 2021
  • 172 locations
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab when compared to nivolumab monotherapy in advanced urothelial cancer patients.

carcinoma
chemotherapy regimen
transitional cell carcinoma
platinum-based chemotherapy
immunomodulator
  • 1 views
  • 27 Jan, 2021
  • 29 locations